PALLAS co-chair Angela DeMichele receives the 2023 Gianni Bonadonna Breast Cancer Award
Researchers with PrECOG, LLC, are presenting updates and new data at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), occurring in Chicago and online during the first weekend in June. Below, please find the essential information for the presentations, along with links to the related abstracts.
For registered virtual attendees, ASCO plans to make most sessions available on demand shortly after their live presentation.
Saturday, June 3
- Gianni Bonadonna Breast Cancer Award — Angela DeMichele, MD, MSCE
Presented during the Opening Session, 9:30 AM | Hall B1
Lecture available only on demand
Dr. DeMichele co-chairs ECOG-ACRIN’s Breast Cancer Committee and is a lead investigator for the PALLAS trial by PrECOG and other international collaborators
- Breast Cancer — Updates on abstract 390216: adjuvant palbociclib for ER+ breast cancer (PALLAS Trial, ABCSG-42/AFT-05/PrE0109/BIG-14-13): a preplanned analysis of the stage IIA cohort
Angela DeMichele, MD, MSCE (University of Pennsylvania)
12:30-1:45 PM CDT (Dr. DeMichele’s presentation begins at 12:36) | Arie Crown Theatre
No abstract available
Part of the ASCO Plenary Series: Rapid Abstract Updates
- Breast Cancer — BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the Oncolytic reovirus pelareorep in combination with paclitaxel and avelumab
Amy S. Clark, MD, MSCE (University of Pennsylvania); Kathy D. Miller, MD (Indiana University)
1:15-2:45 PM CDT (Dr. Clark’s presentation begins at 2:03) | Room S406
Oral Abstract 1012
Part of the Dr. Bernard Fisher Memorial Annual Clinical Science Symposium
Sunday, June 4
- Education Session — Cell cycle inhibition in the clinic: state of the art
Angela DeMichele, MD, MSCE (University of Pennsylvania)
8:00-9:15 AM CDT (Dr. DeMichele’s presentation begins at 8:20) | Room S100a
Part of the ASCO/AACR Joint Session: Targeting the Cell Cycle in Cancer
- Lung Cancer (Mesothelioma) — Trial in Progress — Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: a phase 3, randomized trial (DREAM3R or PrE0506)
Patrick M. Forde, MD (Johns Hopkins University)
8:00-11:00 AM CDT | Poster Board 226a | Hall A
Abstract TPS8599
« Return to News
